Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

NCT00810576 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Terminated due to slow accrual.

Conditions

Lymphoma

Interventions

DRUG: Vorinostat
DRUG: Bortezomib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]